Sanofi adds to COVID-19 pipeline with Translate deal
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
A partnership with Translate Bio to develop an mRNA-based vaccine is one of multiple shots on goal Sanofi is preparing against COVID-19.
The collaboration is part of a 2018 deal in which Sanofi (Euronext:SAN; NASDAQ:SNY) is using the mRNA platform from Translate Bio Inc. (NASDAQ:TBIO) to develop vaccines for up to five infectious diseases.
Translate Bio received $45 million up front and is eligible for $760 million in milestones under the initial deal, and the biotech won’t receive additional funds through the COVID-19 vaccine partnership (see “Sanofi, Translate in mRNA Vaccines Deal”).
Translate said it has begun building multiple mRNA constructs and will use its platform to design and manufacture a number of vaccine candidates; Sanofi will be responsible for further development.
Translate is working with a CMO to increase its manufacturing capacity to two 250-gram batches per month from 100 gram single-batch production.
The deal marks Sanofi's second COVID-19 vaccine partnership. In February, the French pharma partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop a protein-based vaccine.
Sanofi is developing a virus bank using its recombinant DNA vaccine platform; it hopes to begin preclinical testing of a vaccine candidate within five months.
“We believe the more approaches we explore, the better likelihood of success in achieving this goal,” David Loew said in a statement about Sanofi’s work to address the pandemic. He is Sanofi's global head of vaccines.
Sanofi and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are also evaluating IL-6 inhibitor Kevzara sarilumab in an adaptive Phase II/III study to treat COVID-19 patients with severe disease (see "Slotting Anti-inflammatories Into COVID-19 Treatment").
Furthermore, the pharma is part of a consortium co-chaired by Novartis AG (NYSE:NVS; SIX:NOVN) CEO Vas Narasimhan and Bill Gates aimed at speeding development, scaled-up manufacturing and delivery of COVID-19 vaccines, diagnostics and therapies (see "Pharmas to Share Assets in COVID-19 Consortium").
Separately, the University of Oxford said it has started enrolling healthy volunteers, ages 18-55, in its COVID-19 vaccine trial.
The university plans to enroll up to 510 people to receive its ChAdOx1 vaccine in the coming weeks. The vaccine comprises an adenovirus encoding the SARS-CoV-2 spike protein that has been modified so the adenovirus cannot reproduce.
The university signed a contract in February with Italian CMO Advent Srl to produce the first batch of the vaccine.
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus.